J Korean Med Sci.  2017 Sep;32(9):1491-1495. 10.3346/jkms.2017.32.9.1491.

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality

Affiliations
  • 1Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. urofirst@hanmail.net
  • 2Department of Urology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
  • 3Department of Urology, Kosin University College of Medicine, Busan, Korea.
  • 4Department of Urology, Dong-A University College of Medicine, Busan, Korea.
  • 5Department of Urology, Inje University College of Medicine, Busan, Korea.
  • 6Department of Urology, Pusan National University School of Medicine, Busan, Korea.

Abstract

We compared changes in nocturia and sleep-related parameters between daytime and nighttime solifenacin dosing in patents with overactive bladder (OAB) and nocturia. We comparatively analyzed the data of a 12-week prospective, open-label, multicenter, randomized study. All 127 patients who presented to 5 centers in Korea for the treatment of OAB with nocturia between January 2011 and December 2013 were enrolled in this study. The patients were divided into 2 groups by medication timing: group 1, daytime (n = 62); and group 2, nighttime (n = 65). The International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and Athens Insomnia Scale (AIS) were used to assess OAB symptoms and sleep quality. We evaluated the parameter changes before and 12 weeks after daytime or nighttime solifenacin administration. Baseline data, which included sex, age, body mass index (BMI), total AIS, IPSS, and OABSS, did not differ between the 2 groups. Total IPSS, OABSS, and total AIS significantly improved after solifenacin administration regardless of timing (P < 0.001). After solifenacin administration, the number of nocturia episodes decreased in the group 1 and 2 (P < 0.001). There were no significant intergroup differences in changes in AIS, IPSS, OABSS, and number of nocturia episodes 12 weeks after solifenacin administration. Treating OAB with solifenacin may improve nocturia and sleep quality, but advantages did not differ significantly by medication timing.

Keyword

Urinary Bladder, Overactive; Solifenacin Succinate; Nocturia; Sleep

MeSH Terms

Body Mass Index
Humans
Korea
Nocturia*
Prospective Studies
Prostate
Sleep Initiation and Maintenance Disorders
Solifenacin Succinate*
Urinary Bladder, Overactive*
Solifenacin Succinate
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error